Implementing Technologies: Assessment of Telemedicine Experiments in the Paris Region: Reasons for Success or Failure of the Evaluations and of the Deployment of the Projects

Alicia Le Bras (), Kevin Zarca, Maroua Mimouni, Isabelle Durand-Zaleski and ARS Ile de France Telemedicine Group
Additional contact information
Alicia Le Bras: Hôtel Dieu Hospital, URC Eco Ile-de-France (AP-HP), Unité de Recherche Clinique en Économie de la Santé, 1 Place du Parvis Notre Dame, 75004 Paris, France
Kevin Zarca: Hôtel Dieu Hospital, URC Eco Ile-de-France (AP-HP), Unité de Recherche Clinique en Économie de la Santé, 1 Place du Parvis Notre Dame, 75004 Paris, France
Maroua Mimouni: Hôtel Dieu Hospital, URC Eco Ile-de-France (AP-HP), Unité de Recherche Clinique en Économie de la Santé, 1 Place du Parvis Notre Dame, 75004 Paris, France
Isabelle Durand-Zaleski: Hôtel Dieu Hospital, URC Eco Ile-de-France (AP-HP), Unité de Recherche Clinique en Économie de la Santé, 1 Place du Parvis Notre Dame, 75004 Paris, France
ARS Ile de France Telemedicine Group: ARS Ile de France Telemedicine Group is in the Acknowledgments.

IJERPH, 2023, vol. 20, issue 4, 1-13

Abstract: Background: Telemedicine is increasingly viewed as a tool to provide a wide range of health services. This article presents policy lessons drawn from the evaluation of telemedicine experiments conducted in the Paris region. Methods: We used a mixed method design to study telemedicine projects commissioned by the Paris Regional Health Agency between 2013 and 2017. We combined data analysis of the telemedicine projects, review of the protocols, and interviews with stakeholders. Results: We identified the following reasons for disappointing outcomes: the outcome measure was requested too early during the experiments because payers required information for budgetary decisions; and the learning curve, technical problems, diversion of use, insufficient number of inclusions, and a lack of adherence prevented the demonstration of successful outcomes of the projects. Conclusion: The evaluation of telemedicine should be undertaken after sufficient uptake to ensure barriers to implementation are overcome, and to obtain the sample size necessary for statistical power and reduce the average cost for one telemedicine request. Randomized controlled trials should be encouraged with appropriate funding and the follow-up period should be extended.

Keywords: health policy; telemedicine; evaluation (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2023
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/20/4/3031/pdf (application/pdf)
https://www.mdpi.com/1660-4601/20/4/3031/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:20:y:2023:i:4:p:3031-:d:1062773

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().